Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1700a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Dermatitis, Seborrheic, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2024). Roflumilast Foam (Zoryve) for Seborrheic Dermatitis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1700a
Vancouver
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1700a
BibTeX
@article{euvimed2024,
title = {Roflumilast Foam (Zoryve) for Seborrheic Dermatitis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1700a}
}
EUVIMED